Shimmer Launches Verisense Pulse+
Shimmer Research has launched Verisense Pulse+, a new sensor for the Verisense platform. Verisense Pulse+ provides photoplethysmogram, galvanic skin response (GSR), and an inertial measurement unit. The Verisense platform can now measure clinical trial participants’ heart rate, oxygen saturation and emotional responses in addition to their activity and sleep levels.
The PPG sensor monitors heart rate by using light absorption to measure changes in participant capillary blood volume. Whereas the GSR sensor measures changes in sweat gland activity, which can be used to assess the participant’s level of psychological and emotional arousal, stress, and other emotional responses.
For more information, click here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
